Docosahexaenoic acid eliminates endoplasmic reticulum stress and inflammatory pathways in diabetic rat keratopathy
Özet
Diabetic keratopathy, characterized by corneal structural changes, is a common complication of diabetes mellitus (DM). Docosahexaenoic acid (DHA), an omega-3 fatty acid, has shown potential therapeutic benefits in various diabetic complications. This study aimed to investigate the protective effect of DHA on corneal tissue in streptozotocin (STZ)-induced type 2 DM in rats. Forty male Sprague–Dawley rats were randomly assigned to four groups (n = 10 per group): Control, DHA, DM, and DM + DHA. The DHA group received DHA by oral gavage at a dose of 100 mg/kg daily for 10 days. In the DM group, diabetes was induced by a single intraperitoneal injection of STZ at 50 mg/kg. Confirmation of diabetes induction was based on monitoring fasting blood glucose levels on the third day post-injection. The DM + DHA group underwent the same diabetes induction protocol with STZ and received DHA at 100 mg/kg daily via oral gavage for 10 consecutive days. Corneal tissue samples were collected at the end of the study period for histopathological, immunohistochemical, qRT-PCR, and ELISA analyses. Histopathological analysis showed significant edema, angiogenesis, and degeneration in the DM group compared to the control (p < 0.001). DHA treatment significantly mitigated these changes, approaching control levels (p < 0.01). Immunohistochemistry showed increased VEGFR2 and iNOS expression in the DM group, which was significantly reduced in the DM + DHA group (p < 0.01). qRT-PCR results indicated a significant decrease in Bcl-2 expression (p < 0.001) and an increase in ATF-6, IRE1, NF-κB, TNF-α, IL-1β, NLRP3, Bax, and Caspase-3 expressions in the DM group (p < 0.001). ELISA analyses revealed significantly elevated levels of inflammatory markers NF-κB, TNF-α, IL-1β, and IL-6 in the DM group compared to the control (p < 0.001). DHA treatment significantly upregulated Bcl-2 and downregulated apoptotic and inflammatory markers (p < 0.01). DHA demonstrated significant protective effects against STZ-induced corneal damage in diabetic rats by modulating apoptotic and inflammatory pathways. These findings suggest that DHA may be a promising therapeutic agent for preventing diabetic keratopathy. © 2024
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Gezer, Arzu | |
| dc.contributor.author | Özkaraca, Mustafa | |
| dc.contributor.author | Üstündağ, Hilal | |
| dc.contributor.author | Soydan, Menekşe | |
| dc.contributor.author | Alkanoğlu, Ömer | |
| dc.contributor.author | Bedir, Gürsel | |
| dc.date.accessioned | 2026-10-18T20:26:26.765306447Z | |
| dc.date.available | 2026-10-18T20:26:26.765306447Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Diabetic keratopathy, characterized by corneal structural changes, is a common complication of diabetes mellitus (DM). Docosahexaenoic acid (DHA), an omega-3 fatty acid, has shown potential therapeutic benefits in various diabetic complications. This study aimed to investigate the protective effect of DHA on corneal tissue in streptozotocin (STZ)-induced type 2 DM in rats. Forty male Sprague–Dawley rats were randomly assigned to four groups (n = 10 per group): Control, DHA, DM, and DM + DHA. The DHA group received DHA by oral gavage at a dose of 100 mg/kg daily for 10 days. In the DM group, diabetes was induced by a single intraperitoneal injection of STZ at 50 mg/kg. Confirmation of diabetes induction was based on monitoring fasting blood glucose levels on the third day post-injection. The DM + DHA group underwent the same diabetes induction protocol with STZ and received DHA at 100 mg/kg daily via oral gavage for 10 consecutive days. Corneal tissue samples were collected at the end of the study period for histopathological, immunohistochemical, qRT-PCR, and ELISA analyses. Histopathological analysis showed significant edema, angiogenesis, and degeneration in the DM group compared to the control (p < 0.001). DHA treatment significantly mitigated these changes, approaching control levels (p < 0.01). Immunohistochemistry showed increased VEGFR2 and iNOS expression in the DM group, which was significantly reduced in the DM + DHA group (p < 0.01). qRT-PCR results indicated a significant decrease in Bcl-2 expression (p < 0.001) and an increase in ATF-6, IRE1, NF-κB, TNF-α, IL-1β, NLRP3, Bax, and Caspase-3 expressions in the DM group (p < 0.001). ELISA analyses revealed significantly elevated levels of inflammatory markers NF-κB, TNF-α, IL-1β, and IL-6 in the DM group compared to the control (p < 0.001). DHA treatment significantly upregulated Bcl-2 and downregulated apoptotic and inflammatory markers (p < 0.01). DHA demonstrated significant protective effects against STZ-induced corneal damage in diabetic rats by modulating apoptotic and inflammatory pathways. These findings suggest that DHA may be a promising therapeutic agent for preventing diabetic keratopathy. © 2024 | |
| dc.identifier.doi | 10.1016/j.intimp.2024.112871 | |
| dc.identifier.eissn | 1878-1705 | |
| dc.identifier.issn | 1567-5769 | |
| dc.identifier.pmid | 39111146 | |
| dc.identifier.scopus | 2-s2.0-85200481480 | |
| dc.identifier.startpage | 112871 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/11389 | |
| dc.identifier.volume | 140 | |
| dc.identifier.wos | WOS:001291521200001 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | International Immunopharmacology | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Cornea | |
| dc.subject | Diabetes | |
| dc.subject | Docosahexaenoic acid | |
| dc.subject | Animals | |
| dc.subject | Anti-Inflammatory Agents | |
| dc.subject | Apoptosis | |
| dc.subject | Corneal Diseases | |
| dc.subject | Cytokines | |
| dc.subject | Diabetes Mellitus, Experimental | |
| dc.subject | Docosahexaenoic Acids | |
| dc.subject | Endoplasmic Reticulum Stress | |
| dc.subject | Male | |
| dc.subject | Rats | |
| dc.subject | Rats, Sprague-Dawley | |
| dc.subject | Streptozocin | |
| dc.subject | caspase 3 | |
| dc.subject | inducible nitric oxide synthase | |
| dc.subject | interleukin 1beta | |
| dc.subject | interleukin 6 | |
| dc.subject | omega 3 fatty acid | |
| dc.subject | tumor necrosis factor | |
| dc.subject | antiinflammatory agent | |
| dc.subject | cytokine | |
| dc.subject | adult | |
| dc.subject | angiogenesis | |
| dc.subject | animal experiment | |
| dc.subject | animal model | |
| dc.subject | animal tissue | |
| dc.subject | Article | |
| dc.subject | controlled study | |
| dc.title | Docosahexaenoic acid eliminates endoplasmic reticulum stress and inflammatory pathways in diabetic rat keratopathy | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 9 | |
| rdl.citation.wos | 9 | |
| rdl.department | Department of Physiology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkiye. Electronic address: hilal.ustundag@erzincan.edu.tr. | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
